@Phaedrus you've made good points and these inspections may add additional timeline to commercialisation.
However, what duty of care do the FDA have to check the QA of manufacturing when they allow for P1, P2 and P3 trials?
Would they have performed some inspections already?
MSB 2022 - The road to commercialisation, page-20
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |